A series of talks with experts in herpes simplex virus research, commercial partners in vaccine or treatment development, sexual health, and more.
Learn more about clinical trials, the latest science, advances in technology, and the role of patient advocacy.
UPenn/BioNTech Clinical Trials: Latest updates and Q&A with Dr Harvey Friedman
January 11th, 6pm EST
Dr. Harvey Friedman
Dr. Harvey Friedman is Professor of Medicine/Infectious Disease at University of Pennsylvania.
Join to learn the latest on the BioNTech clinical trials. Recruiting for clinical trials in the US has begun – join to learn more about the research of Dr. Friedman and his team.
Pritelivir: Latest updates from Aicuris January 25th 5pm EST
Alexander Birkman: Head of Research
Dr. Hubert Trubel: Chief Medical Officer and Head of Clinical Development
Pritelivir is currently in clinical trials in more than 70 locations globally.
Dr TJ Cradick: Excision Biotherapeutics
February 1st, 6pm EST
Join Dr. TJ Cradick, Chief Scientific Officer at Excision Biotherapeutics to learn about Excision Bio pre-clinical work in gene therapy for Herpes Simplex. Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients. A recognized expert in genome editing technologies, Dr. Cradick has developed nucleases, as well as genome editing and gene therapy reagents and methods for CRISPR/Cas nuclease, TAL Effector Nucleases (TALENs) and Zinc Finger Nucleases (ZFNs), both in his academic work at University of Iowa and the Georgia Institute of Technology, and in-industry at Sangamo Therapeutics (NASDAQ: SGMO).
Dr Keith Jerome: Fred Hutch Cancer Center
February 22nd, 6pm EST
Professor, Vaccine and Infectious Disease Division
Dr. Keith Jerome is a renowned virologist whose research focuses on viruses such as herpes simplex, HIV and hepatitis B that persist in their hosts. He studies the ways in which these viruses evade the immune system and potential therapies for these infections. Dr. Jerome and The Jerome Lab are currently in pre-clinical development with a gene therapy to cure latent HSV.
Betsy C. Herold, M.D.: Harold and Muriel Block Chair, Dept. of Pediatrics
March 22nd 6pm EST
Professor and Vice Chair for Research, Department of Pediatrics and Microbiology-Immunology. Chief, Division of Pediatric Infectious Diseases
Albert Einstein College of Medicine
Betsy Herold, M.D. directs a basic and translational research program, which focuses on the prevention of HIV and HSV and other viral infections. Basic research in the lab focuses on the development of a novel vaccine candidate that protects against HSV-1 and HSV-2 in multiple rigorous small animal models by eliciting antibodies that provide sterilizing protection through antibody-dependent killing. The lab is also developing monoclonal antibodies to treat and prevent HSV. The vaccine is being advanced to the clinic by X-vax Technology.
Terri Warren, BA, M.Ed, BSN, MSN
April 26th, 6pm EST
Terri Warren has served as principal investigator or sub-investigator on more than 120 clinical trials evaluating various testing mechanisms for sexually transmitted infections, the efficacy of experimental vaccines, and pharmacologic interventions for numerous human infections. Her area of special expertise is the herpes simplex virus.
Dr. Gary Richwald: Herpes Cure Advocacy
May 24th, 6pm EST
Join for a discussion with Herpes Cure Advocacy medical advisory board member Dr. Gary Richwald. Learn about the latest advances in herpes simplex virus cure, treatment and prevention efforts in the US and globally, how to advocate for change, the role of the patient advocate and more.